Skip to main content

Table 1 Antiretroviral exposure status of 220 HIV-positive infants analysed for resistance associated mutations over the 3 South African Prevention of Mother to Child Transmission Evaluations

From: Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4–8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011–12 and 2012–13

 

2010 survey

2011–12 survey

2012–13 survey

Total

Maternal ART plus infant NVP +/− AZT

10 (10%)

11 (14%)

13 (32%)

34 (15%)

Maternal ARV plus infant NVP+/− AZT

33 (33%)

23 (29%)

7 (17%)

63 (29%)

Infant NVP+/−AZT only

11 (11%)

10 (13%)

5 (12%)

26 (12%)

Any other ARV combination

10 (10%)

3 (4%)

2 (5%)

15 (7%)

No/unknown exposure

37 (37%)

31 (40%)

14 (34%)

82 (37%)

Total

101

78

41

220

  1. ART triple drug antiretroviral therapy, ARV: antiretroviral therapy administered to prevent mother to child transmission